Nov 19, 2026: a takeover report sends Insmed up 17%

Insmed closed Wednesday, Nov 18, at $119.80 and was flat before the open, at $119.75 at 8:00am. It opened at $119.50, dipped to $118.00, its session low, in the first minutes, and traded near $121 for the first half hour.

At 10:04am the stock jumped from about $121.60 to $128.03 on 232,000 shares in one minute as the report spread. Trading then stopped for about ten minutes. When it reopened at 10:15am the stock printed its session high of $148.94, up 24.3%, and then slipped to $137.77 by 10:19am as early buyers took profits. It held between $138 and $141 for the next hour, with 7.4 million shares traded by 11:11am, already about twice the 20-day average for a full day.

What pushed it up:

  • The buyer. Sanofi is one of the largest drugmakers in the world, with a market value of about $112.5 billion at today's price, close to four times Insmed's.
  • The timing. On Oct 20 Insmed added Paul Hudson, a former Sanofi chief executive, to its board. That is not evidence of talks, but it is a direct line between the two companies that the market noticed today.
  • The launch. BRINSUPRI treats non-cystic fibrosis bronchiectasis, a chronic lung disease, and Insmed still expects peak sales of more than $7 billion. A buyer that needs new growth would pay for that curve.

The rest of the group did not move with Insmed. At about 11:08am the SPDR S&P Biotech ETF was flat, the iShares Biotechnology ETF was down 0.4%, Vertex was down 2.6% and United Therapeutics, a rival in inhaled treprostinil, was down 2.8%. The gap points to the takeover report and nothing broader. Our explainer on what a takeover premium is covers how buyers price a bid against the undisturbed share price, and more of the session's movers are in today's biggest stock moves.

After the jump, RSI(14) stood at 76, the shares sat 27% above their 50-day average and 14% above their 200-day average, and volume ran 2.0 times its 20-day average with most of the session still to go. The stock remained 34% below its 52-week high.

The numbers

MeasureQ3 2026Q2 2026Q1 2026Q3 2025
Total revenue$524.4M$425.5M$306.0M$142.3M
BRINSUPRI revenue$400.1M$309.2M$207.9M$28.1M
ARIKAYCE revenue$124.4M$116.3M$98.1M$114.3M
Cash and securities$1.1B$1.2B$1.2B

BRINSUPRI grew 49% from the first quarter to the second and 29% from the second to the third. Nine-month BRINSUPRI revenue was $917.1 million, so the raised full-year range of $1.35 billion to $1.4 billion implies $433 million to $483 million in the fourth quarter. ARIKAYCE guidance rose to $460 million to $470 million, and the FDA granted Priority Review to its expanded MAC lung disease filing, with a decision due Jan 28, 2027.

Spending is rising with the launch and the pipeline. Third-quarter research and development costs were $270.0 million, up from $186.4 million a year earlier, mostly for TPIP, and selling, general and administrative costs were $253.0 million, up from $186.4 million. The net loss narrowed to $100.3 million, or $0.46 a share, from $370.0 million a year earlier. Our guide on how to read an 8-K for catalysts shows where these figures sit in a results filing.

Bar chart of BRINSUPRI revenue: $28.1 million in Q3 2025, $207.9 million in Q1 2026, $309.2 million in Q2 2026 and $400.1 million in Q3 2026

The bull case

The launch is beating its own guidance. BRINSUPRI started 2026 with guidance of at least $1 billion, then $1.25 billion to $1.4 billion in the second quarter, and now $1.35 billion to $1.4 billion. Chief executive Will Lewis said on Oct 29 that the U.S. launch "continues to exceed expectations," and the drug launched in Japan in October. Behind it, TPIP is in Phase 3 in pulmonary hypertension with interstitial lung disease, pulmonary arterial hypertension and progressive pulmonary fibrosis, with a fourth study in idiopathic pulmonary fibrosis planned for the first half of 2027. Insmed puts TPIP's peak sales above $6 billion. A stock that fell from $212.75 to $90.39 on a failed sinus trial has rebuilt on a launch that is working, and a bid would put a price on that progress. If talks continue, other buyers could compete, as the report itself said.

The risks

  • No deal. Reports of early talks often end without an offer. Without a bid, the takeover hope in today's price would likely fade toward the Nov 18 close.
  • Valuation. At about 20 times sales and a forward P/E near 205, the stock needs BRINSUPRI to keep growing fast. A slower fourth quarter would weigh on it with or without Sanofi.
  • Pipeline setbacks. Brensocatib already failed in chronic rhinosinusitis without nasal polyps in December 2025, when neither dose beat placebo, and Insmed ended that program. TPIP results are years away.
  • Deal terms. A bid near today's price would leave little upside from here. Our explainer on merger arbitrage covers how a spread forms once terms are set, and our piece on what happens to options in an acquisition explains how contracts settle.

What comes next

  1. Any statement from Sanofi or Insmed. A confirmed approach, an offer or a denial would set the price more than anything else in the window.
  2. Dec 1, 2026. Insmed presents at the Evercore ISI healthcare conference, its first public appearance since the report.
  3. Fourth-quarter BRINSUPRI revenue. The range implied by guidance is $433 million to $483 million.
  4. Jan 28, 2027. The FDA action date for ARIKAYCE in MAC lung disease. Our guide on how to build a catalyst calendar shows how to track dates like these.